## Oxervate (cenegermin-bkbj) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:		
important for the review	at all applicable sections complete (e.g., chart notes or lab data, to s alth Information under HIPAA.			
			URGENT	
MEMBER INFORMATION	N			
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:		l .		
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID	NUMBER:			
IF YOU ARE NOT THE PATIENT OR THE P FOLLOWING LINK: PRIMETHERAPEUTIC	HEIGHT (IN/CM): WEIG PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISC S.COM/NOPP  REPRESENTATIVE (IF APPLICABLE	CLOSURE AUTHORIZATION FORM WITH THIS R	REQUEST WHICH CAN BE FOUND AT THE	
	TATIVE'S PHONE NUMBER:			
PRESCRIBER INFORMAT	ION			
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:		<u> </u>		
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
		1		
MEDICATION OR MEDIC	CAL DISPENSING INFORMATION			
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
NEW THERAPY DURATION OF THERAPY	RENEWAL (SPECIFIC DATES):	IF RENEWAL: DATE THERA	PY INITIATED:	

Continued on next page



## Oxervate (cenegermin-bkbj) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
☐ Satege 2 Persistent epithelial defect(PED☐ Stage 3 Corneal ulcer due to neurotroph			
☐ Other diagnosis:ICD-	10		
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION. Clinical Information:	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A	
Is drug being used as part of a clinical	trial? □ Yes □ No		
Has patient used Oxervate(cenegermi	n) previously?   Yes   No Please provid	le dates of treatment.	
Does the patient's neurotrophric kera	topathy affect both eyes? ☐ Yes ☐ No		
Has the patient had the keratopathy f	or at least 2 weeks?   Yes   No		
	test or Cochet-Bonnet aesthesiometer) or corneal ulcer?   Yes   No Please prov		
Did the Sensitivity test also demonstrate area of the defect? ☐ Yes ☐ No Please	ate a decreased corneal sensitivity in at provide chart documentation.	least one quadrant outside of the	
lenses, autologous serum tears, amnie	at least one of the following: punctal on th	correction of concomitant lid	
,	y or conjunctival flap procedure?   injection to induce pharmacological blo		
Does the patient have any active ocul	ar infection or inflammation UNRELATE	D to neurotrophic keratopathy?	
Are there any other comments, diagnophysician feels is important to this rev	oses, symptoms, medications tried or fa riew?	iled, and/or any other information the	



## Oxervate (cenegermin-bkbj) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:		
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required		
information is received.		
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.  Prescriber Signature or Electronic I.D. Verification: Date:		
CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If		
you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents		
of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX)		
and arrange for the return or destruction of these documents.		

**FAX THIS FORM TO: 800-424-7640** 

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP – 4201
P.O. Box 64811

St. Paul, MN 55164-0811

